,i #aahth ,,congress #b;d ,session ,h4 ,r4 #gbdh ,,in ,,the ,,house ,,of ,,representatives ,february #f1 #bjbd,mr4 ,carter of ,georgia 7for himself1 ,ms4 ,barragn1 ,mrs4 ,harshbarger1 ,mr4 ,buchanan1 ,mr4 ,carter of ,louisiana1 ,mr4 ,waltz1 ,ms4 ,de,lauro1 ,mr4 ,nehls1 ,mr4 ,gooden of ,texas1 ,mr4 ,crenshaw1 and ,mr4 ,fitzpatrick7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to establish a process for the qualification of nonclinical testing methods to reduce and replace the use of animals in nonclinical research1 improve the predictivity of nonclinical testing methods1 and reduce development time for a biological product or other drug1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,,fda ,modernization ,act #c4j4 #b4 ,nonclinical testing methods qualification process at the ,food and ,drug ,administration 7a7 ,in general ,subchapter ,a of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cea et seq47 is amended by inserting after section #ejg the following3 #ejg;,a4 ,nonclinical testing methods qualification process 7a7 ,in general 7#a7 ,process description ,the ,secretary shall establish a process for the qualification of a nonclinical testing method1 with respect to drugs1 under which-- 7,a7 persons may request qualification of a nonclinical testing method for a particular context of use2 and 7,b7 the ,secretary shall grant or deny such request in accordance with this section4 7#b7 ,initiation ,the ,secretary shall initiate the process under paragraph 7#a7 not later than #a year after the date of enactment of this section4 7b7 ,eligible nonclinical testing methods ,to be eligible for qualification under this section1 a nonclinical testing method shall-- 7#a7 be intended to replace or reduce animal testing2 and 7#b7 either-- 7,a7 improve the predictivity of nonclinical testing for safety and efficacy2 or 7,b7 reduce development time for a drug 7including any biological product74 7c7 ,qualification of nonclinical testing methods 7#a7 ,process ,the ,secretary shall establish a process for submission of a request under subsection 7a74 7#b7 ,contents ,at a minimum1 a request under subsection 7a7 shall include preliminary information demonstrating that the nonclinical testing method meets the criteria described in subsection 7b7 in a particular context of use4 7#c7 ,advice regarding the method of nonclinical testing ,the ,secretary may facilitate the development and review of preliminary information submitted pursuant to paragraph 7#b7 in a request under subsection 7a7 by-- 7,a7 providing timely advice to1 and interaction with1 the person submitting the request regarding the development of the method of nonclinical testing2 and 7,b7 involving senior managers and experienced staff of the ,food and ,drug ,administration1 as appropriate1 in a collaborative1 cross-disciplinary review of the proposed method of nonclinical testing4 7#d7 ,engagement of external experts ,in reviewing a request under subsection 7a71 the ,secretary may-- 7,a7 through the use of cooperative agreements or other appropriate mechanisms1 consult with biomedical research consortia and other expert stakeholders with specific expertise in nonclinical testing methods2 and 7,b7 consider recommendations of biomedical research consortia or other qualified experts in deciding whether to grant or deny the request4 7#e7 ,review of requests 7,a7 ,timing ,not later than #ahj calendar days after the receipt of a request under subsection 7a71 the ,secretary shall determine whether to grant or deny the request4 7,b7 ,determination ,in reviewing a nonclinical testing method pursuant to a request under subsection 7a71 the ,secretary shall determine whether to grant or deny the request based on whether the method satisfies the criteria listed in subsection 7b7 as demonstrated by-- 7i7 the information submitted in the request or supplements thereto2 and 7ii7 any additional information provided by external experts4 7,c7 ,qualification decision ,if the ,secretary determines pursuant to subparagraph 7,b7 that a nonclinical testing method satisfies the criteria listed in subsection 7b71 the ,secretary shall grant the request for qualification of the method in a particular context of use4 7d7 ,effects of qualification ,if the ,secretary qualifies a nonclinical testing method pursuant to a request under this section-- 7#a7 the method shall be available for use by the holder of the qualification or a person authorized by such holder for drug development in the particular context of use for which the method is qualified2 and 7#b7 the ,secretary shall-- 7,a7 expedite the development and review of an application submitted under section #eje of this ,act or section #cea of the ,public ,health ,service ,act1 including supplemental applications1 for drugs that are developed using the qualified nonclinical testing method2 and 7,b7 allow the holder of the qualification or a person authorized by such holder to reference or rely upon1 in an application submitted under section #eje of this ,act or section #cea of the ,public ,health ,service ,act1 including a supplemental application1 data and information about the qualification of the nonclinical testing method in the same context of use for which the qualification was granted4 7e7 ,review of applications utilizing qualified nonclinical testing methods ,the ,secretary shall expedite the development and review of an application submitted under section #eje of this ,act or section #cea of the ,public ,health ,service ,act for drugs for which a nonclinical testing method qualified under this section is used4 7f7 ,transparency 7#a7 ,submission of report to ,congress ,not later than #b years after the date of enactment of this section and annually thereafter1 the ,secretary shall publish on the website of the ,food and ,drug ,administration and submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives a report containing an evaluation of the process under this section4 7#b7 ,contents of report ,each report under paragraph 7#a7 shall include-- 7,a7 for the period covered by the report-- 7i7 the types of nonclinical testing methods qualified under the process2 7ii7 the number of requests for qualification under subsection 7a71 and the number of such requests that have been granted2 7iii7 the average number of calendar days for the review of requests under subsection 7a7 before granting or denying such requests2 7iv7 an analysis of the factors that result in determinations to qualify or not qualify a nonclinical testing method under this section2 and 7v7 the number of applications received under section #eje of this ,act or section #cea of the ,public ,health ,service ,act that rely on a nonclinical testing method qualified under this section1 and the number of such applications approved2 and 7,b7 for the period beginning on the date of enactment of this section through the end of the period covered by the report1 the number of animals estimated to have been saved as a result of the process under this section4 7g7 ,nonclinical testing method defined ,in this section1 the term nonclinical testing method has the meaning given to such term in section #eje7z7 except that such term excludes any animal test4 4 7b7 ,public meeting ,not later than #ahj days after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services shall publish in the ,federal ,register a notice to convene a public meeting to discuss and obtain input and recommendations from relevant stakeholders1 including regulated industry1 biomedical consortia1 contract research organizations1 and patients1 regarding-- 7#a7 the goals and scope of the process under #ejg;,a of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a72 7#b7 a framework1 procedures1 and requirements for such process2 and 7#c7 ways in which the ,food and ,drug ,administration will support the use of nonclinical testing methods to replace or reduce the use of animals in nonclinical testing4 7c7 ,,fda guidance 7#a7 ,nonclinical testing methods qualification process ,the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 shall-- 7,a7 not later than #a year after the date of the public meeting under subsection 7b71 propose guidance on the goals and implementation of the process under section #ejg;,a of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a72 7,b7 provide a period for public comment on such proposed guidance2 and 7,c7 not later than #a year after the end of such public comment period1 finalize such guidance4 7#b7 ,contents ,the guidance under paragraph 7#a7 shall address-- 7,a7 the process by which a person may request qualification under section #ejg;,a of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a72 7,b7 the eligibility criteria under subsection 7b7 of such section #ejg;,a2 7,c7 the information that a person requesting such qualification is required to submit under subsection 7c7 of such section #ejg;,a2 and 7,d7 how the ,secretary intends to evaluate requests under such section #ejg;,a4 #c4 ,regulations on nonclinical testing methods 7a7 ,in general ,not later than #ij days after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 shall initiate a rulemaking under section #eec of title #e1 ,united ,states ,code1 to implement section #eje7z7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7z774 7b7 ,technical amendment ,section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 is amended by designating the second subsection 7z7 7relating to clinical trial diversity action plans71 as added by section #cfja7;a7 of the ,health ,extenders1 ,improving ,access to ,medicare1 ,medicaid1 and ,,chip1 and ,strengthening ,public ,health ,act of #bjbb 7division ,,ff of ,public ,law #aag-cbh71 as subsection 7aa74